12 $10 Stocks That Will Triple
In this article, we discuss 12 $10 stocks that will triple. If you want to skip our discussion on the latest stock market landscape, head over to 5 $10 Stocks That Will Triple. According to JPMorgan,...
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
5.64 | |
5.4 | |
- | |
5.68 | |
5.285 | |
3.25-10.45 | |
478 M | |
84 796 K | |
0 | |
-0.14 | |
0.614 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we discuss 12 $10 stocks that will triple. If you want to skip our discussion on the latest stock market landscape, head over to 5 $10 Stocks That Will Triple. According to JPMorgan,...
Investors might want to bet on Anavex Life Sciences (AVXL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings es...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: